Recent preclinical models demonstrate that dual PI3K/mTOR inhibitors not only suppress CRC cell proliferation but also sensitize tumors to ferroptotic death pathways, presenting a multifaceted opportunity for immune modulation [115]. The gene discussed is MTOR; the disease is colorectal carcinoma.